2004
Requests for reprints can be addressed to:
de Boer AH, Hagedoorn P, Gjaltema D, Frijlink HW
Comparative in vitro performance evaluation of the Novopulmon 200 Novolizer and Budesonid-ratiopharm Jethaler: two novel budesonide dry powder inhalers
de Boer AH, Hagedoorn P, Gjaltema D, Lambregts D, Irngartinger M, Frijlink HW
The rate of drug particle detachment from carrier crystals in an air classifier-based inhaler
Pharm Res, 21, 2158-2166, 2004
de Boer AH, Hagedoorn P, Gjaltema D, Lambregts D, Irngartinger M, Frijlink HW
The mode of drug particle detachment from carrier crystals in an air classifier-based inhaler
Pharm Res, 21, 2167-2174, 2004
de Boer AH, Hagedoorn P, Gjaltema D, Le Brun PPH, Frijlink HW
Meer mogelijkheden met ‘(multiple) air classifier’-technology
de Boer AH, Hagedoorn P, Le Brun PPH, Frijlink HW
Instructies bij het gebruik van inhalatoren
Bouwman AM, Bosma JC, Vonk P, Wesselingh JA, Frijlink HW
Which shape factor(s) best describe granules?
Powder Techn, 146, 66-72, 2004
Bouwman AM, Visser MR, Eissens AC, Wesselingh JA, Frijlink HW
The effect of vessel material on granules produced in a high-shear mixer
Eur J Pharm Sci, 23, 169-179, 2004
Le Brun PPH, de Boer AH, Frijlink HW
Werkingsprincipes en eigenschappen van toedieningsvormen voor inhalatie
van Drooge DJ, Hinrichs WLJ, Frijlink HW
Incorporation of lipophilic drugs in sugar glasses by lyophilization using a mixture of water and tertiary butyl alcohol as solvent
J Pharm Sci, 93, 713-725, 2004
van Drooge DJ, Hinrichs WLJ, Wegman KAM, Visser MR, Eissens AC, Frijlink HW
Solid dispersions based on inulin for the stabilisation and formulation of Δ9-tetrahydrocannabinol
Eur J Pharm Sci, 21, 511-518, 2004
van Drooge DJ, Hinrichs WLJ, Frijlink HW
Anomalous dissolution behaviour of tablets prepared from sugar glass-based solid dispersions.
J Control Release, 97, 441-452, 2004
Eriksson HJC, Mol R, Somsen GW, Hinrichs WLJ, Frijlink HW, de Jong GJ
Feasibility of nonvolatile buffers in capillary electrophoresis-electrospray ionization-mass spectrometry of proteins
Electrophoresis, 23, 43-49, 2004
Frijlink HW, de Boer AH
Dry powder inhalers for pulmonary delivery
Expert Opin Drug Deliv, 1, 67-86, 2004
Frijlink HW, Le Brun PPH, Brouwers JRBJ
Waarom geavanceerd ook zinvol is
Frijlink HW, de Boer AH
Systemische toediening van geneesmiddelen via de long
Irngartinger M, Camuglia V, Damm M, Goede J, Frijlink HW
Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturing
Eur J Pharm Biopharm, 58, 7-14, 2004
Rigter IM, Schipper HG, Koopmans RP, van Kan HJM, Frijlink HW, Kager PA, Guchelaar HJ
Relative bioavailability of three newly developed albendazole formulations: a randomized crossover study with health volunteers
Antimicrob Agents Chemother, 48, 1051-1054, 2004
van der Veen B, van der Voort Maarschalk K, Bolhuis GK, Frijlink HW
Predicting mechanical properties of compacts containing two components
Powder Techn, 139, 156-164, 2004
Westerman EM, Le Brun PPH, Touw DJ, Frijlink HW, Heijerman HGM
Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study
J Cystic Fibrosis, 3, 23-28, 2004
Zijlstra GS, Boersma C, Frijlink HW, Postma MJ
Pharmacoeconomic review of recombinant human dNase in the management of cystic fibrosis
Expert Rev Pharmacoeconomics Outcomes Res, 4(1), 49-59, 2004
Zijlstra GS, Hinrichs WLJ, de Boer AH, Frijlink HW
The role of particle engineering in relation to formulation and de-agglomeration principle in the development of a dry powder formulation of cetrorelix
Eur J Pharm Sci, 23, 139-149, 2004
Laatst gewijzigd: | 09 januari 2020 10:20 |